Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Lipoxen Technologies Limited patents


Recent patent applications related to Lipoxen Technologies Limited. Lipoxen Technologies Limited is listed as an Agent/Assignee. Note: Lipoxen Technologies Limited may have other listings under different names/spellings. We're not affiliated with Lipoxen Technologies Limited, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "L" | Lipoxen Technologies Limited-related inventors


Method for treatment of primary hormone resistant endometrial and breast cancers

The invention provides a method for treatment of primary progesterone receptor-negative (pr−) endometrial cancer comprising administering (i) cridanimod or a salt or an ester thereof and (ii) a progesterone receptor (pr) agonist. The invention further provides a method for treatment of a primary estrogen receptor-negative (er−) breast cancer, comprising administering (i) cridanimod or a salt or an ester thereof and (ii) a selective estrogen receptor modulator (serm) or a selective estrogen receptor down-regulator (serd). ... Lipoxen Technologies Limited

Method for treatment of primary hormone resistant endometrial and breast cancers

The invention provides a method for treatment of primary progesterone receptor-negative (pr−) endometrial cancer comprising administering (i) cridanimod or a salt or an ester thereof and (ii) a progesterone receptor (pr) agonist. The invention further provides a method for treatment of a primary estrogen receptor-negative (er−) breast cancer, comprising administering (i) cridanimod or a salt or an ester thereof and (ii) a selective estrogen receptor modulator (serm) or a selective estrogen receptor down-regulator (serd). ... Lipoxen Technologies Limited

Derivatisation of erythropoietin (epo)

The present invention relates to a compound which is a polysaccharide derivative of epo, or of an epo like protein, wherein the polysaccharide is anionic and comprises between 2 and 200 saccharide units. The present invention also relates to pharmaceutical compositions comprising the novel compounds, and methods for making the novel compounds.. ... Lipoxen Technologies Limited

Derivatisation of granulocyte colony-stimulating factor

The present invention relates to a compound which is a polysaccharide derivative of gcsf, or of a gcsf like protein, wherein the polysaccharide is anionic and comprises between 2 and 200 saccharide units. The present invention also relates to pharmaceutical compositions comprising the novel compounds, and methods for making the novel compounds.. ... Lipoxen Technologies Limited

N-terminal derivatisation of proteins with polysaccharides

The present invention relates to methods for producing n-terminal derivatives of proteins in which a polysaccharide, preferably having at least terminal sialic units, and preferably consisting essentially only of sialic acid units, is reacted at the n-terminus of a protein or peptide under controlled conditions to produce an n-terminal derivative. The controlled conditions include use of acidic ph for the derivatisation step and a higher ph for purification. ... Lipoxen Technologies Limited

Method to enhance an immune response of nucleic acid vaccination

A composition comprising liposomes associated with a nucleic acid operatively encoding an antigenic protein and with an assistor protein, wherein the assistor protein shares at least one epitope with the antigenic protein, and wherein the nucleic acid and said assistor protein are associated with the same liposomes is described. The composition provides an improved immune response compared to mixtures of liposomes some of which are associated with the nucleic acid and some of which are associated with the assistor protein.. ... Lipoxen Technologies Limited

Sialic acid derivatives for protein derivatisation and conjugation

Derivatives are synthesized of starting materials, usually polysaccharides, having sialic acid at the reducing terminal end, in which the reducing terminal unit is transformed into an aldehyde group. Where the polysaccharide has a sialic acid unit at the non-reducing end it may be passivated, for instance by converting into hydroxyl-substituted moiety. ... Lipoxen Technologies Limited








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Lipoxen Technologies Limited in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Lipoxen Technologies Limited with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###